Research Article

Research to Observe the Hemodynamic Changes and Cardiac Function in Active Abdominal Compression-decompression Cardiopulmonary Resuscitation

Yingxin Cen¹, Sisen Zhang¹,²*, Hongwei Wang¹, Ting Liu¹, Longxian Zhao³, Cunqing Zhang⁴, Jing Li⁴ and Lixiang Wang⁵

¹The second School of Clinical Medicine, Southern Medical University, Guangzhou, 510280, Guangdong, China
²Zhengzhou People’s Hospital, Zhengzhou, 450003, Henan, China
³Sanmenxia Central Hospital, Sanmen, 472000, Henan, China
⁴Beijing GMR Medical Equipment Company,Ltd, Beijing, 100038, China
⁵Chinese People’s Armed Police General Hospital, Beijing, 100038, China

ARTICLE INFO

Article history:
Received: 22 November, 2018
Accepted: 18 December, 2018
Published: 31 December, 2018

Keywords:
Transthoracic echocardiography
cardiac arrest
cardiopulmonary resuscitation
haemodynamics
cardiac function

ABSTRACT

Objective: Compare the hemodynamic changes and cardiac function between active abdominal compression-decompression cardiopulmonary resuscitation and standard cardiopulmonary resuscitation.

Methods: A prospective controlled trial was conducted. The patients staying in EICU or ICU were the study subjects which were divided into active abdominal compression-decompression cardiopulmonary resuscitation (AACD-CPR) group and standard cardiopulmonary resuscitation (STD-CPR) group randomly. Central venous pressure (CVP), diastolic blood pressure (DBP) and coronary perfusion pressure (CPP) were recorded continuously. Transesophageal echocardiography (TEE) was used to observe the cardiac valves and assess left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV), left ventricular ejection fraction (LVEF) during CPR.

Results: During CPR, LVEDV of two groups both decreased compared with pre-cardiac arrest, which was not statistically significant (P>0.05). LVEDV in AACD-CPR group was larger than STD-CPR group during CPR. But there was not statistically significant (P>0.05). During CPR, LVESV of two groups both increased compared with pre-cardiac arrest, which was statistically significant (P<0.01). LVESV in AACD-CPR group was larger than STD-CPR group (P<0.05). But there was not statistically significant (P>0.05). Both AACD-CPR group and STD-CPR group showed significantly decreased LVEF compared with pre-cardiac arrest, of which the difference was statistically significant (P<0.01). LVEF in STD-CPR group was higher than AACD-CPR group and there was a statistically significant difference between them (P<0.05). When compressing chest, mitral valve and tricuspid valve were open and aortic valve and pulmonary valve were closed during the 8 patients of the STD-CPR group.

Conclusion: During chest compression, heart pump took effect in a part of patients. However, during abdominal compression, heart was just a channel that blood flowed. The cardiac function in STD-CPR was superior to AACD-CPR. However, both of them can produce effective haemodynamics. So, we suggested that AACD-CPR could be used in the patients with the contraindication of STD-CPR.

© 2018 Zhang Sisen. Hosting by Science Repository. All rights reserved.

*Correspondence to: Zhang Sisen, The second School of Clinical Medicine, Southern Medical University, Guangzhou, 510280, Guangdong, China; Email: 2362176700@qq.com

© 2018 Zhang Sisen. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository. All rights reserved.
http://dx.doi.org/10.31487/j.JICOA.2018.01.006
Introduction

Cardiac arrest is a catastrophic disease. More than 544,000 died of cardiac arrest in China yearly [1]. So, it is important to conduct a timely and effective CPR. Although emergency medical service (EMS) and the awareness of CPR have been improved, the morbidity and mortality of cardiac arrest is still very high [2]. With decades of development since its emergence, CPR has improved survival rates and return of spontaneous circulation (ROSC) to some extent, but it is still below expectation. Traditional CPR can’t satisfy the current clinical request. We urgently need new techniques. On the basis of predecessors’ researches, Wang et al. came up with active abdominal compression-decompression cardiopulmonary resuscitation (AACD-CPR) innovatively which solves the problems of standard cardiopulmonary resuscitation (STD-CPR) and can be used in patients with chest deformity, rib fracture, etc [3]. AACD-CPR generates effective circulating blood flow and ventilation through several mechanisms including “abdominal pump”, “thoracic pump”, and “lung pump” [3].

The purpose of this study was to compare the hemodynamic changes and cardiac function between AACD-CPR and STD-CPR.

Methods and materials

I Patients

This was a prospective study conducted at Zhengzhou People’s Hospital from January 2017 to June 2018. We selected inpatients from Intensive Care Unit (ICU). Inclusion/exclusion criteria are as follows. Finally, there were 47 patients selected into our research. According to the contraindications, 15 patients which had the contraindications of chest compression were selected into AACD-CPR group. The other patients were selected into STD-CPR group.

Inclusion criteria

i. Patients with cardiac arrest that need CPR according to the 2015 AHA guidelines.
ii. The age were more than 18 years old.
iii. Patients had no contraindication of STD-CPR and AACD-CPR. The contraindication of STD-CPR was chest deformity, rib fracture and so on. The contraindication of AACD-CPR was the rupture of abdominal organ, abdominal mass, abdominal aortic aneurysm, pregnancy.
iv. Body weight between 40kg-150kg

Exclusion criteria

i. The patients had the history of myocardiopathy, valvular disease or pericardial disease, such as myocardial hypertrophy, dilated cardiomyopathy, narrow pericarditis and so on.
ii. Patients with end-stage disease or cachexia.
iii. Patients had contraindications of STD-CPR and AACD-CPR

II Ethical Approval

All the trials got the approval of the Ethical Review Committee of Zhengzhou People’s Hospital and Sanmenxia center Hospital (the number of approvals: 2014-006-03). All patient relatives or legal guardians received a detailed explanation of the study’s possible risks and benefits and were permitted to request discontinuation of the study at any time.

III Clinical intervention

i. All patients had colour doppler echocardiography when they were admitted into ICU. We recorded left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV) and left ventricular ejection fraction (LVEF) of patients.
ii. All patients were monitored through electrocardiograph. And we performed central venous catheterization and invasive arterial pressure measurement for all of them.
iii. When CA happens, all patients received orotracheal intubation, respiration with the aid of a rebreathing bag or breathing machine, electric defibrillation and epinephrine apart from AACD-CPR or STD-CPR.

IV The usage of CPR-LW1000 abdominal lifting/compression device

Using the instrument, the operator should hold the pressure application handles and place the compression plate on the patient’s abdomen. After turning on the device, negative pressure is generated which causes a tight bond between these pressure plates and the patient’s abdomen. The operator then presses an indicator light prompted by an audio signal with a frequency of 100 times/minute, and the instrument performs alternate vertical downward compressions and upward lifting actions. The duration of compression and lifting was performed in a 1:1 interval, the pressure was approximately 186mmHg when the indicator light was on, and lifting force was approximately 112 mmHg. Images of the device are shown.

V Methods

When CA happens, our emergency response team immediately performs STD-CPR or AACD-CPR and Transesophageal echocardiography. We recorded the LVEDV, LVESV and LVEF. At the same time, we recorded the DBP and CVP 5 minutes after CPR.

VI Termination of Lifesaving Treatmen

According to 2015 AHA guideline: i) spontaneous artery pulsation. ii) ruddy complexion. iii) spontaneous respiration. iv) retraction of pupils and light reflex. After rescuing for more than 30 minutes and giving the agreement of patients’ family, we would stop rescuing if the patients didn’t restore spontaneous artery pulsation and spontaneous respiration.

VII Observational index

LVEDV, LVESV and LVEF before CA and during CPR.
DBP and CVP before CA and 5 minutes after CPR.
Coronary perfusion pressure (CPP)=DBP-CVP

VIII Statistical Analysis

Statistical analysis was performed by using the SPSS 20.0 statistical software. Data with normal distribution were presented as
mean±standard deviation. The ranked data were presented as mean rank. Analysis for categorical variable were performed using X2 test. The two-sample t-test was applied for comparison of continuous variables between the two groups. The ranked data were tested with the Mann-Whitney-Wilcoxon test. A probability value of p < 0.05 was considered to be statistically significant difference.

Results

The differences in age, sex and weight in two groups are not statistically significant (P>0.05), as is shown in (Table 1).

LVEDV, LVESV and LVEF in two groups before and during CA were shown in (Table 2). During CPR, LVEDV of two groups both decreased compared with pre-cardiac arrest stage, which was not statistically significant (P>0.05). However, during CPR, LVESV of two groups were larger than pre-cardiac arrest, which was statistically significant (P<0.01). LVEF of two groups both decreased compared with pre-cardiac arrest, which was statistically significant (P<0.01). During CPR, LVEDV of two groups were not statistically significant (P>0.05). However, LVESV of AACD-CPR group was larger than the STD-CPR group (P<0.05). The difference of LVEF in two groups was statistically significant (P<0.05). LVEF of STD-CPR group were larger than AACD-CPR group.

In the STD-CPR group, there were 8 patients which mitral and tricuspid valves closed, and aortic and pulmonary valves opened during chest compressions. The four valves in the other patients opened. The four valves in AACD-CPR group all opened.

DBP, CVP and CPP in two groups before and during CA were shown in (Table 3). There was no statistically significant difference in DBP, CVP, CPP between the two groups before CA (P>0.05). Both AACD-CPR group and STD-CPR group showed significantly decreased DBP compared with pre-cardiac arrest stage, of which the difference was statistically significant (P<0.01). There was no statistically significant difference in DBP, CVP and CPP between the two groups during CPR (P>0.05).

Table 1: The general information of two group

| group      | age        | size | weight          | Etiology | epinephrine (mg) | defibrillation (time) | Time:CPR (min) | ROSC(n,%) |
|------------|------------|------|-----------------|----------|------------------|-----------------------|----------------|-----------|
|            | male       | female |                 | cardiogenic | Non-cardiogenic |                       |                 |           |
| STD-CPR    | 60.75±21.29 | 18    | 14              | 21       | 11               | 7.72±2.25             | 0.88±1.10       | 32.0±19.72 | 3 (9,4)   |
| AACD-CPR   | 56.30±16.4 | 9     | 6               | 7        | 8                | 7.87±3.0              | 0.73±0.88       | 30.67±19.35 | 1 (6,7)   |
| Χ²: t value| 0.54       | 0.059 | -0.277          | 1.524    | -0.189           | 0.432                 | 0.217           | 0.096     |
| P value    | 0.595      | 0.808 | 0.785           | 0.217    | 0.851            | 0.665                 | 0.829           | 0.756     |

PS: STD-CPR standard cardiopulmonary resuscitation; AACD-CPR active abdominal compression-decompression cardiopulmonary resuscitation

Table 2: The comparison of cardiac function between two groups

| group      | N       | LVEDV(ml)          | LVESV(ml)          | LVEF    |
|------------|---------|--------------------|--------------------|---------|
|            |         |                    |                    |         |
| STD-CPR (before CA) | 32       | 106.53±19.12        | 64.74±20.72        | 0.38±0.098 |
| AACD-CPR (before CA) | 15       | 111.58±17.97        | 71.51±18.17        | 0.36±0.117 |
| STD-CPR (during CPR) | 32       | 97.76±16.43         | 83.5±13.41         | 0.09±0.038 |
| AACD-CPR (during CPR) | 15       | 108.06±15.85        | 103.3±14.79        | 0.04±0.048 |
| 1 : 2 t value | -0.633  | -0.092              | -0.352             |         |
| 1 : 2 P value | 0.534   | 0.928               | 0.728              |         |
| 1 : 3 t value | 1.893   | -2.79               | 8.211              |         |
| 1 : 3 P value | 0.072   | 0.047               | 0.000              |         |
| 2 : 4 t value | 0.465   | -4.290              | 7.933              |         |
| 2 : 4 P value | 0.648   | 0.000               | 0.000              |         |
A Computer-based Study on the Effect of Sympathetic Activity during CPR

Table 3: The comparison of haemodynamics between two groups

| Group                        | N  | DBP (mmHg) | CVP (mmHg) | CPP (mmHg) |
|------------------------------|----|------------|------------|------------|
| (5) STD-CPR (before CA)      | 32 | 69.75±16.89| 9.33±5.94  | 60.42±16.08|
| (6) AACD-CPR (before CA)     | 15 | 70.70±13.75| 9.10±4.72  | 61.60±14.63|
| (7) STD-CPR (during CPR)     | 32 | 46.67±8.01 | 11.5±6.61  | 35.17±11.17|
| (8) AACD-CPR (during CPR)    | 15 | 50.90±7.87 | 11.9±4.98  | 39.0±11.66 |

\[ \begin{align*}
\text{(3) \& (4)} &: t \text{ value} & -1.21 & -3.292 & 2.895 \\
\text{(3) \& (4)} &: P \text{ value} & 0.057 & 0.040 & 0.009
\end{align*} \]

PS: STD-CPR standard cardiopulmonary resuscitation; AACD-CPR active abdominal compression-decompression cardiopulmonary resuscitation; LVEDV left ventricular end diastolic volume; LVESV left ventricular end systolic volume; LVEF left ventricular ejection fraction

Discussion

CPR has been used for more than 60 years and rescued large numbers of patients. With the development of medicine and update of the guideline, researchers have invented many techniques to improve ROSC rate. However, the ROSC rate is still unsatisfactory. European resuscitation guide indicated that during CPR, the volume of blood flowing through the heart and cardiac output were important factors which would impact ROSC rate [4]. In 1967, Jr et al firstly added abdominal compression during chest compressions in order to increase returned blood volume and cardiac output [5]. After decades of research, many studies indicated that interposed abdominal compression cardiopulmonary resusciation (IAC-CPR) can improve DBP, CPP and ROSC rate [6-8]. However, if patients have contraindication of chest compression, such as chest deformity, pneumothorax, and rib fracture etc., doctors don’t know what to do. In 2007, a study of pig ventricular fibrillation model, Geddes et al from American Purdue University indicated that abdominal compression (OAC-CPR) alone produced 60% more coronary perfusion than standard chest-compression CPR, with no damage to visceral organs [9]. On the basis of pre-research, Wang innovatively invented the CPR-LW1000 abdominal lifting/compression device and proposed AACD-CPR.

AACD-CPR, a new technique, pulls up the abdominal wall with a negative pressure device after compressing the abdomen, which decreases the pressure of abdominal cavity, lowers the diaphragm, increases the pressure of thoracic cavity, decreases the pressure of right atrium and vena cava, and increases the returned blood volume. When the abdomen is compressed, the pressure of abdominal cavity increases and the organs in abdomen are compressed, causing blood to flow into heart. In addition, with increased pressure in the abdominal cavity, the diaphragm moves up, the volume of thoracic cavity decreases, and the pressure increases, and the heart enters a systolic state, causing cardiac ejection [3]. During OAC-CPR and STD-CPR, the abdominal wall or thorax restores passively. Moreover, STD-CPR has the risk of rib fracture, which affects the restoration of thorax and lowers the ROSC rate [10, 11]. AACD-CPR can avoid the risk of rib fracture and increase returned blood volume. Animal trial and human trial also demonstrated that AACD-CPR produces effective blood circulation and potentially improves ROSC rate [12-15].

Our result indicated that LVEDV of AACD-CPR group was larger than that of STD-CPR group, because organs in abdomen account for 1/4 of total blood volume and when the abdomen was compressed, the organs were compressed and volume of blood returning to heart increased [16]. Geddes et al pointed out in a study with swine model that when the pigs

Journal of Integrative Cardiology Open Access doi: 10.31487/j.JICOA.2018.01.006 Volume 1(1): 4-7
were normal the mean of coronary perfusion index was 4016 mmHg and when the pigs were in the state of VF, the mean of coronary perfusion index was 922 mmHg, indicating that OAC-CPR provided 1/4 of blood volume, whereas standard chest-compression CPR provided only 17%(645/3781) [19]. There was a statistically significant difference in LVESV between the two groups and the AACD-CPR group was larger than the STD-CPR group. The result showed that the strength for cardiac compression in STD-CPR was stronger than AACD-CPR. STD-CPR generates artificial circulation via “thoracic pump” and “heart pump”. When the sternum was compressed, the heart, which is positioned between sternum and spine, is pressed directly. Then atriocentral valve closes, aortic valve opens, and finally the heart shrinks and generates ongoing blood flow [17]. In AACD-CPR, increased pressure within the abdominal cavity caused the the diaphragm to move up, the volume of the thoracic cavity decreases, and the pressure increases, and the heart is pressed indirectly, causing cardiac ejection and blood flowing ahead [13]. LVEVDV and LVESV. The result means that the cardiac function during AACD-CPR is the same as STD-CPR. In our study, 32 patients underwent chest compressions of which only 8 patients had cardiac pump mechanism, and 24 patients did not see atriocentral valve closure. In the AACD-CPR group, all patients had no atriocentral valve closure and almost no heart compression. Therefore, the cardiac pump did not play a role in AACD-CPR, and the heart only served as a channel for blood flow.

Our result showed that DBP of two groups had no statistically significant difference. The result was the same as our previous research result [18].

In 1990, Paradis et al discovered when CPP was more than 15mmHg, the rate of ROSC would increase. The higher CPP, the higher the rate of ROSC [19]. Up to now, CPP is still used to predict the survival rate [20]. Kammeyer et al indicated that rhythm abdominal compression generated higher CPP than STD-CPR [21]. Georgiou et al also indicated that compared with STD-CPR, CPP was significantly higher in IAC-CPR–treated animals. Although our result didn’t get a statistically significant difference between two groups, CPP in AACD-CPR was higher than STD-CPR [22].

Conclusion

Hemodynamics and cardiac function in AACD-CPR was as the same as STD-CPR. We suggested that AACD-CPR could be used in the patients with the contraindication of STD-CPR and the elder.

Limitation

There are limitations to this study that should be considered. The study was performed at a single center, and the number of patients was limited. Autopsies were not performed in no survivors and thus we were not able to determine if abdominal lifting and compression resulted in abdominal injuries.

Competing Interests

The authors declare that they have no competing interests.

Acknowledgments

The study was funded by Zhengzhou Technological Leadership Personnel Focal Project (131PLJRC682) and key support project of Science and technology Benefiting the people of Henan province (152207310007)

Fund program

Key support project of Science and technology Benefiting the people of Henan province (152207310007); Zhengzhou City Key Supporting Project of Innovative Science and Technology Leading Talents of Henan Province (131PLJRC682).

REFERENCES

1. Blauwhoff-Buskeremolen S, Versteeg KS, de van der Schuuren MA, den Braver NR, Berkhof J et al. (2016) Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. J Clin Oncol 34: 1339-1344. [Crossref]
2. Park I, Choi SJ, Kim YS, Ahn HK, Hong J et al. (2016) Prognostic Factors for Risk Stratification of Patients Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy. Cancer Res Treat 48: 1264-1273. [Crossref]
3. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC (2009) Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer. Clin Cancer Res 15: 6973-6979. [Crossref]
4. Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin MT et al. (2013) Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index. J Clin Oncol 31: 1539-1547. [Crossref]
5. Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R et al. (2015) Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer. PloS One 10: e0129742. [Crossref]
6. Arrieta O, De la Torre-Vallejo M, Lopez-Macias D, Orta D, Turcott J et al. (2015) Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. Oncologist 20: 967-974. [Crossref]
7. Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A et al. (2014) Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 66: 583-589. [Crossref]
8. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ et al. (2011) An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67: 93-101. [Crossref]
9. Choi Y, Oh DY, Kim TY, Lee KH, Han SW et al. (2015) Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. PloS One 10: e0139749. [Crossref]
10. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol* 12: 489-495. [Crossref]

11. Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT et al. (2006) Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C-SCANS Study. *JAMA Oncol* 3: e172319. [Crossref]

12. Pantano Nde P, Paiva BS, Hui D, Paiva CE (2016) Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care. *J Pain Symptom Manage* 51: 270-277. [Crossref]

13. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. *Br J Cancer* 94: 637-641. [Crossref]

14. Bouca-Machado R, Rosario M, Alarcao J, Correira-Guedes L, Abreu D et al. (2017) Clinical trials in palliative care: a systematic review of their methodological characteristics and of the quality of their reporting. *BMJ Palliat Care* 16: 10. [Crossref]

15. Johanna Nattenmuller, Raoul Wochner, Thomas Muley, Martin Steins, Simone Hummler et al. (2017) Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemo-therapy in Lung Cancer Patients. *PloS One* 12: e0169136. [Crossref]

16. Hough R, Sandhu S, Khan M, Moran A, Felbtower R et al. (2017) Are survival and mortality rates associated with recruitment to clinical trials in teenage and young adult patients with acute lymphoblastic leukaemia? A retrospective observational analysis in England. *BMJ Open* 7: e017052. [Crossref]

17. Obeng SR, Wilson BV, Peiffer P, Kjeldsen J (2017) Home Parenteral nutrition increases fat free mass in patients with incurable gastrointestinal cancer. Results of a randomised controlled trial. *Clin Nutr* 38: 182-190. [Crossref]

18. Oken MM, Creech RH, Torney DC, Horton J, Davis TE et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655. [Crossref]

19. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z (2003) Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. *Clin Nutr* 22: 321-336. [Crossref]

20. Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. *Nutrition* 5: 303-311. [Crossref]

21. Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ et al. (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. *Appl Physiol Nutr Metab* 33: 997-1006. [Crossref]

22. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D et al. (1985) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. *J Appl Physiol* 85: 115-122. [Crossref]

23. Heymsfield SB, Wang Z, Baumgartner RN, Ross R (1997) Human body composition: advances in models and methods. *Annu Rev Nutr* 17: 527-558. [Crossref]

24. Roeland EJ, Ma JD, Nelson SH, Seibert T, Heavey S et al. (2017) Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials. *Support Care Cancer* 25: 365-369. [Crossref]

25. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M et al. (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. *Clin Cancer Res* 15: 2920-2926. [Crossref]

26. Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S et al. (2016) Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. *Cancer Med* 5: 607-616. [Crossref]

27. Csepedes Feliciano EM, Lee VS, Prado CM, Meyerhardt JA, Alexeiff S (2017) Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study. *Cancer* 123: 4868-4877. [Crossref]

28. Soubeyran P, Fonck M, Blanc-Bisson C, Blanc J-F, Cecchaldi J et al. (2012) Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer. *J Clin Oncol* 30: 1829-1834. [Crossref]

29. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD et al. (2011) Predicting Chemotherapy Toxicity in older Adults With Cancer: A Prospective Multicenter Study. *J Clin Oncol* 29: 3457-3465. [Crossref]

30. Hopkins JJ, Sawyer MB (2017) A review of body composition and pharmacokinetics in oncology. *Expert Rev Clin Pharmacol* 10: 947-956. [Crossref]

31. Kaasa S, Hjermstad MJ, Loge JH (2006) Methodological and structural challenges in palliative care research: how have we fared in the last decades? *Palliat Med* 20: 727-734. [Crossref]

32. Nipp RD, El-Jawhari A, Moran SM, D Apino SM, Johnson PC et al. (2017) The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer. *Cancer* 123: 4720-4727. [Crossref]

33. Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD (2007) Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. *Cochrane Database Syst Rev* 16: MR000009. [Crossref]

34. Peppercorn JM, Weeks JC, Cook EF, Joffe S (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. *Lancet* 363: 263-270. [Crossref]

35. Julian-Reynier C, Geneve J, Dalenc F, Genre D, Monnier A et al. (2007) Assessment of Care by Breast Cancer Patients Participating or Not Participating in a Randomized Controlled Trial: A Report With the Patients' Committee for Clinical Trials of the Ligue Nationale Centre le Cancer. *J Clin Oncol* 25: 3038-3044. [Crossref]
36. Reid J, McKenna HP, Fitzsimons D, McCance TV (2010) An exploration of the experience of cancer cachexia: what patients and their families want from healthcare professionals. *Eur J Cancer Care (Engl)* 19: 682-689. [Crossref]

37. White CD, Hardy JR, Gilshenan KS, Charles MA, Pinkerton CR (2008) Randomised controlled trials of palliative care - a survey of the views of advanced cancer patients and their relatives. *Eur J Cancer* 44: 1820-1828. [Crossref]

38. Ling J, Rees E, Hardy J (2000) What influences participation in clinical trials in palliative care in a cancer centre? *Eur J Cancer* 36: 621-626. [Crossref]

39. Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB et al. (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. *Lancet Oncol* 9: 629-635. [Crossref]

40. Rollins KE, Tewari N, Ackner A, Awwad A, Madhusudan S, et al. (2016) The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. *Clin Nutr* 35: 1103-1109. [Crossref]